Impact of Distinct Anti-Androgen Exposures on the Plasma Metabolome in Feminizing Gender-Affirming Hormone Therapy
CONCLUSION: Our results suggest an anti-atherogenic signature in the plasma metabolome after the first six months of feminizing GAHT, with cyproterone acetate also reducing specific plasma amino acids. This study provides novel insight into the metabolic changes occurring across feminizing GAHT.PMID:38609170 | DOI:10.1210/clinem/dgae226 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 12, 2024 Category: Endocrinology Authors: Rebecca Shepherd Lachlan M Angus Toby Mansell Bridget Arman Bo Won Kim Katherine Lange David Burgner Jessica A Kerr Ken Pang Jeffrey D Zajac Richard Saffery Ada Cheung Boris Novakovic Source Type: research
Impact of Distinct Anti-Androgen Exposures on the Plasma Metabolome in Feminizing Gender-Affirming Hormone Therapy
CONCLUSION: Our results suggest an anti-atherogenic signature in the plasma metabolome after the first six months of feminizing GAHT, with cyproterone acetate also reducing specific plasma amino acids. This study provides novel insight into the metabolic changes occurring across feminizing GAHT.PMID:38609170 | DOI:10.1210/clinem/dgae226 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 12, 2024 Category: Endocrinology Authors: Rebecca Shepherd Lachlan M Angus Toby Mansell Bridget Arman Bo Won Kim Katherine Lange David Burgner Jessica A Kerr Ken Pang Jeffrey D Zajac Richard Saffery Ada Cheung Boris Novakovic Source Type: research
Effect of Spironolactone and dbcAMP-Ca Combination Therapy on Clinical Outcomes and Left Ventricular Function in Chronic Heart Failure Patients Post Percutaneous Coronary Intervention
CONCLUSIONS: The combination therapy of spironolactone and dbcAMP-Ca holds potential as an effective treatment strategy for CHF patients following PCI. This combination therapy demonstrated superior clinical efficacy, improved left ventricular function, and enhanced autonomic nerve function, with reduced adverse reactions and biomarker levels. Spironolactone combined with dbcAMP-Ca can be considered as a beneficial treatment strategy for CHF patients post-PCI. The demonstrated clinical efficacy, improvement in left ventricular function, and enhanced autonomic nerve function support the wider application of this combination...
Source: Alternative Therapies in Health and Medicine - March 29, 2024 Category: Complementary Medicine Authors: Li Ye Sijia Tu Source Type: research
Effect of Spironolactone and dbcAMP-Ca Combination Therapy on Clinical Outcomes and Left Ventricular Function in Chronic Heart Failure Patients Post Percutaneous Coronary Intervention
CONCLUSIONS: The combination therapy of spironolactone and dbcAMP-Ca holds potential as an effective treatment strategy for CHF patients following PCI. This combination therapy demonstrated superior clinical efficacy, improved left ventricular function, and enhanced autonomic nerve function, with reduced adverse reactions and biomarker levels. Spironolactone combined with dbcAMP-Ca can be considered as a beneficial treatment strategy for CHF patients post-PCI. The demonstrated clinical efficacy, improvement in left ventricular function, and enhanced autonomic nerve function support the wider application of this combination...
Source: Alternative Therapies in Health and Medicine - March 29, 2024 Category: Complementary Medicine Authors: Li Ye Sijia Tu Source Type: research
Effect of Spironolactone and dbcAMP-Ca Combination Therapy on Clinical Outcomes and Left Ventricular Function in Chronic Heart Failure Patients Post Percutaneous Coronary Intervention
CONCLUSIONS: The combination therapy of spironolactone and dbcAMP-Ca holds potential as an effective treatment strategy for CHF patients following PCI. This combination therapy demonstrated superior clinical efficacy, improved left ventricular function, and enhanced autonomic nerve function, with reduced adverse reactions and biomarker levels. Spironolactone combined with dbcAMP-Ca can be considered as a beneficial treatment strategy for CHF patients post-PCI. The demonstrated clinical efficacy, improvement in left ventricular function, and enhanced autonomic nerve function support the wider application of this combination...
Source: Alternative Therapies in Health and Medicine - March 29, 2024 Category: Complementary Medicine Authors: Li Ye Sijia Tu Source Type: research
Effect of Spironolactone and dbcAMP-Ca Combination Therapy on Clinical Outcomes and Left Ventricular Function in Chronic Heart Failure Patients Post Percutaneous Coronary Intervention
CONCLUSIONS: The combination therapy of spironolactone and dbcAMP-Ca holds potential as an effective treatment strategy for CHF patients following PCI. This combination therapy demonstrated superior clinical efficacy, improved left ventricular function, and enhanced autonomic nerve function, with reduced adverse reactions and biomarker levels. Spironolactone combined with dbcAMP-Ca can be considered as a beneficial treatment strategy for CHF patients post-PCI. The demonstrated clinical efficacy, improvement in left ventricular function, and enhanced autonomic nerve function support the wider application of this combination...
Source: Alternative Therapies in Health and Medicine - March 29, 2024 Category: Complementary Medicine Authors: Li Ye Sijia Tu Source Type: research
Effect of Spironolactone and dbcAMP-Ca Combination Therapy on Clinical Outcomes and Left Ventricular Function in Chronic Heart Failure Patients Post Percutaneous Coronary Intervention
CONCLUSIONS: The combination therapy of spironolactone and dbcAMP-Ca holds potential as an effective treatment strategy for CHF patients following PCI. This combination therapy demonstrated superior clinical efficacy, improved left ventricular function, and enhanced autonomic nerve function, with reduced adverse reactions and biomarker levels. Spironolactone combined with dbcAMP-Ca can be considered as a beneficial treatment strategy for CHF patients post-PCI. The demonstrated clinical efficacy, improvement in left ventricular function, and enhanced autonomic nerve function support the wider application of this combination...
Source: Alternative Therapies in Health and Medicine - March 29, 2024 Category: Complementary Medicine Authors: Li Ye Sijia Tu Source Type: research
Effect of spironolactone on survival in patients undergoing maintenance hemodialysis
This study aimed to evaluate survival according to the use of spironolactone in a large sample of patients undergoing maintenance HD. MethodsThis retrospective study used laboratory and clinical data from the national HD Quality Assessment Program and claims data. The participants of the quality assessment program were patients who had been undergoing maintenance HD for ≥ 3 months, patients undergoing HD at least twice a week. Patients with no spironolactone prescription during the assessment periods were designated as the control group. Patients with one or more prescriptions of spironolactone during the assessment peri...
Source: PLoS One - March 29, 2024 Category: Biomedical Science Authors: Seok Hui Kang Source Type: research
Efficacy and Predictive Factors of Oral Spironolactone Treatment in Chronic Central Serous Chorioretinopathy
CONCLUSIONS: This study suggested that oral spironolactone could be an effective and safe therapy for chronic CSC patients. Eyes with a higher baseline SFCT and intact ellipsoid zone could have a good response. These parameters are an important prognostic marker.PMID:38529362 | PMC:PMC10963119 | DOI:10.1155/2024/7197249 (Source: Journal of Ophthalmology)
Source: Journal of Ophthalmology - March 26, 2024 Category: Opthalmology Authors: Sheng Gao Yun Zhang Meixia Zhang Source Type: research
Proteomic profiles of left atrial volume and its influence on response to spironolactone: Findings from the HOMAGE trial and STANISLAS cohort
ConclusionIn individuals without heart failure, LAVi was associated with MMP-2, IGFBP-2 and NT-proBNP. Spironolactone reduced these biomarker concentrations as well as LAVi and PICP, irrespective of left atrial size. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - March 26, 2024 Category: Cardiology Authors: Masatake Kobayashi,
Jo ão Pedro Ferreira,
Duarte Kevin,
Emmanuel Bresso,
Olivier Huttin,
Erwan Bozec,
Hans‐Peter Brunner La Rocca,
Christian Delles,
Andrew L. Clark,
Frank Edelmann,
Arantxa González,
Stephane Heymans,
Pierpaolo Pellicori, Tags: Research Article Source Type: research
